Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953315 · ClinicalTrials.gov registry record · Phase 1
Muscle Progenitor Cell Therapy for Urinary Incontinence
A Phase 1 study of Urinary Incontinence, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT01953315: Completed Phase 1 study of Urinary Incontinence, sponsored by Wake Forest University.
NCT01953315 is a Phase 1 study of Urinary Incontinence that has completed, run by Wake Forest University. The registered enrollment target is 10 participants, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01953315, a Phase 1 study of Urinary Incontinence, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate the safety of muscle progenitor cells (MPCs) for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).
Primary Outcome
the subject/biopsy/treatment site will be monitored for signs of bleeding, infection, continued pain, prolonged hospitalization
Conditions Studied
Interventions
- BIOLOGICAL Autologous Muscle Progenitor Cells
Study Locations (2)
North Carolina
- Wake Forest Urology Clinic - Winston-Salem
- Wake Forest Institute for Regenerative Medicine (WFIRM) - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
What the finished NCT01953315 record still lists
NCT01953315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Autologous Muscle Progenitor Cells is the first listed.
NCT01953315 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01953315 about?
NCT01953315 is a clinical study titled "Muscle Progenitor Cell Therapy for Urinary Incontinence". This study is designed to evaluate the safety of muscle progenitor cells (MPCs) for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).
What is the current status of trial NCT01953315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2018-01.
What conditions does trial NCT01953315 study?
This clinical trial studies the following conditions: Urinary Incontinence.
What interventions are being tested in trial NCT01953315?
The interventions under investigation include: Autologous Muscle Progenitor Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01953315?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01953315 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01953315's enrollment target sits among peer trials
10 46th of 48 the lowest of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Muscle Fiber Fragment Treatment for Urinary Incontinence
RECRUITING · Phase 1
-
Use of Sildenafil for Treatment of Urinary Incontinence
ACTIVE NOT RECRUITING · Phase 1
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia